WordNet
- impervious to being affected; "resistant to the effects of heat"; "resistant to persuasion"
- a deficiency of red blood cells (同)anaemia
- a lack of vitality (同)anaemia
- a glycoprotein secreted by the kidneys that stimulates the production of red blood cells
- genus of terrestrial or lithophytic ferns having pinnatifid fronds; chiefly of tropical America (同)genus Anemia
PrepTutorEJDIC
- 抵抗力のある;(…に)抵抗する《+『to』+『名』》
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
- 1. 透析前および腹膜透析患者における慢性腎疾患の貧血のためのエリスロポエチン erythropoietin for the anemia of chronic kidney disease among predialysis and peritoneal dialysis patients
- 2. 貧血を有する成人患者に対するアプローチ approach to the adult patient with anemia
- 3. 心不全を有する成人における貧血に対するアプローチ approach to anemia in adults with heart failure
- 4. 貧血を有する小児に対するアプローチ approach to the child with anemia
- 5. 成人における溶血性貧血の診断へのアプローチ approach to the diagnosis of hemolytic anemia in the adult
English Journal
- Evaluation of the effect of pentoxifylline on erythropoietin-resistant anemia in hemodialysis patients.
- Mohammadpour AH, Nazemian F1, Khaiat MH, Tafaghodi M, Salari P, Charkazi S, Naghibi M, Shamsara J.Author information 1Nephrology Ward, Department of Internal Medicine, Imam-Reza Hospital, Mashhad University of Medical Sciences, Mashhad, Iran.AbstractUse of recombinant human erythropoietin (rh-Epo) improves hemoglobin (Hgb) in 90-95% of the cases of anemia of chronic kidney disease (CKD). However, it is known that pro-inflammatory cytokines such as interferon-gamma (IFN-γ), tumor necrosis factor-alfa (TNF-α) and interleukin-1 (IL-1) suppress erythropoiesis, resulting in inadequate response to rh-Epo. Pentoxifylline has been shown to have modulatory effects on the immune system. This prospective study to evaluate the effect of pentoxyphylline on erythropoeisis was performed on 15 (eight males, seven females) clinically stable patients who had been on hemodialysis for at least six months with anemia (Hgb of <10.7 g/dL) unresponsive to rh-Epo despite high doses. They were treated with 400 mg pentoxifylline tablets once daily for 12 weeks. Hgb increased after one and two months of drug administration, but significant changes were observed in eight (53%) patients after three months (P <0.05). Our study illustrates a probable new use for an old medicine. Three months treatment with pentoxifylline was seen to increase Hgb significantly in rh-Epo-resistant patients. More prospective studies with a larger sample size are needed to determine the inhibitory role of cytokines on hematopoiesis and exploring new drugs or new drug indications to overcome anemia in advanced renal failure.
- Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.Saudi J Kidney Dis Transpl.2014 Jan;25(1):73-8.
- Use of recombinant human erythropoietin (rh-Epo) improves hemoglobin (Hgb) in 90-95% of the cases of anemia of chronic kidney disease (CKD). However, it is known that pro-inflammatory cytokines such as interferon-gamma (IFN-γ), tumor necrosis factor-alfa (TNF-α) and interleukin-1 (IL-1) suppress e
- PMID 24434385
- Massive bone marrow involvement in an end stage renal failure case with erythropoietin-resistant anemia and primary hyperoxaluria.
- Taşlı F1, Özkök G, Ok ES, Soyer N, Mollamehmetoğlu H, Vardar E.Author information 1Department of Pathology, Bozyaka Training and Research Hospital, Izmir, Turkey. fundadr@gmail.comAbstractPrimary hyperoxaluria is a rare autosomal recessive disorder. Type 1 PH is the most common form and develops due to a defect in a liver specific enzyme the alanine aminotransferase enzyme. As a result of the enzyme deficiency, there is an overproduction of oxalate and excessive urinary excretion. Recurrent urolithiasis and nephrocalcinosis are the most important findings of the disorder and often at the beginning end-stage renal disease develops. This report presents a case backed up by literature of a patient with end stage renal failure and erythropoietin-resistant anaemia whose bone marrow biopsy showed crystal deposition which received delayed diagnosis of oxalosis.
- Renal failure.Ren Fail.2013 Sep;35(8):1167-9. doi: 10.3109/0886022X.2013.815564. Epub 2013 Jul 23.
- Primary hyperoxaluria is a rare autosomal recessive disorder. Type 1 PH is the most common form and develops due to a defect in a liver specific enzyme the alanine aminotransferase enzyme. As a result of the enzyme deficiency, there is an overproduction of oxalate and excessive urinary excretion. Re
- PMID 23879652
- Interventions for erythropoietin-resistant anaemia in dialysis patients.
- Badve SV1, Beller EM, Cass A, Francis DP, Hawley C, Macdougall IC, Perkovic V, Johnson DW.Author information 1Department of Nephrology, Princess Alexandra Hospital, Woolloongabba, QLD, Australia, 4102.AbstractBACKGROUND: People living with end-stage kidney disease (ESKD) often develop anaemia. Erythropoiesis-simulating agents (ESAs) are often given to people living with ESKD to maintain haemoglobin at a level to minimise need for transfusion. However, about 5% to 10% of patients with ESKD exhibit resistance to ESAs, and observational studies have shown that patients requiring high doses of ESA are at increased risk of mortality.
- The Cochrane database of systematic reviews.Cochrane Database Syst Rev.2013 Aug 26;8:CD006861. doi: 10.1002/14651858.CD006861.pub3.
- BACKGROUND: People living with end-stage kidney disease (ESKD) often develop anaemia. Erythropoiesis-simulating agents (ESAs) are often given to people living with ESKD to maintain haemoglobin at a level to minimise need for transfusion. However, about 5% to 10% of patients with ESKD exhibit resista
- PMID 23979995
Japanese Journal
- 血液透析患者に対する経口・静注L-カルニチン補充療法がカルニチン濃度に与える影響とその効果についての検討
- 深水 圭,酒井 和子,甲斐田 裕介,大塚 紹,和田 芳文,杉 健三,奥田 誠也
- 日本透析医学会雑誌 47(6), 367-374, 2014
- 血液透析 (HD) 患者におけるカルニチン欠乏は, 貧血や低栄養を惹起しQOLを低下させる. 最近わが国において透析患者に対するL-カルニチン経口・静注治療が可能となり, その効果が期待されている. 今回, HD患者に対する6か月間のL-カルニチン900mg経口投与が貧血や栄養状態にいかに影響するかについて, さらに500mg, 1,000mg静注への切り替えによりカルニチン濃度がどのように推移 …
- NAID 130004542544
- 慢性腎不全・骨髄異形成症候群合併症例における鉄過剰症に対する経口鉄キレート剤の効果と安全性
- 福井 真二,鳥本 一匡,影林 頼明 [他],森本 勝彦,山口 惣一,濱野 一將,三馬 省二
- 日本透析医学会雑誌 = Journal of Japanese Society for Dialysis Therapy 42(11), 865-869, 2009-11-28
- 症例は76歳，男性．1995年4月に右腎細胞癌に対して右腎摘除術を受けた後，徐々に腎機能が低下し，2006年2月に血液透析が導入された．前医で維持透析中，右副腎腫瘍およびエリスロポエチン抵抗性貧血が出現し，2008年5月に当科へ紹介された．副腎腫瘍は転移性と考えられた．また，MRI T2強調像で肝は著明な低信号を示し，肝ヘモクロマトーシスが疑われた．血清フェリチン値は2,314ng/mLと高値で， …
- NAID 10026315800
- エリスロポエチン不応性貧血にダルベポエチンが奏効した赤芽球癆, 副腎機能不全合併の長期透析患者の1例
- 清水 阿里,武井 卓,青木 明日香 [他],杉浦 秀和,秋葉 隆,新田 孝作
- 日本透析医学会雑誌 = Journal of Japanese Society for Dialysis Therapy 42(4), 339-344, 2009-04-28
- エリスロポエチン不応性貧血にダルベポエチンαが奏効した赤芽球癆，副腎機能不全合併の長期透析患者の1例を経験した．症例はIgA腎症を原疾患とする慢性腎不全のため1988年5月（45歳）より血液透析導入，透析中の64歳男性である．2000年（57歳），2005年（62歳）に腎癌を合併し，両側の腎臓を摘出．以後も外来維持透析されていたが，低血圧および貧血の進行が認められたため，精査加療目的に2007年9 …
- NAID 10024930825
Related Links
- Anne E Dar Santos Anne E Dar Santos BSc(Pharm), at time of writing, Clinical Pharmacist, Pharmaceutical Sciences Clinical Services Unit, Vancouver General Hospital, Vancouver, British Columbia, Canada ...
- ... therapy suggests that this is a real effect. The patients in this study had experienced erythropoietin-resistant anemia for a minimum of 6 mo before receiving pentoxifylline, and some of them had shown Although the reduction 31 ...
Related Pictures
★リンクテーブル★
| リンク元 | 「エリスロポエチン不応性貧血」 |
| 関連記事 | 「resistant」「erythropoietin」 |
「エリスロポエチン不応性貧血」
「resistant」
- adj.
- 抵抗性の、耐性の、抵抗する